AGRX · Agile Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.58M | $5.72M | - | $6.66M | $5.50M | $3.81M | - | $3.00M | $2.13M | $1.76M |
| Cost of Revenue | $1.50M | $1.68M | - | $2.48M | $2.31M | $2.00M | - | $1.43M | $2.23M | $1.53M |
| Gross Profit | $4.08M | $4.04M | - | $4.18M | $3.20M | $1.81M | - | $1.58M | ($105.0K) | $234.0K |
| R&D | $538.0K | $495.0K | - | $705.0K | $703.0K | $763.0K | - | $788.0K | $856.0K | $1.26M |
| SG&A | $2.51M | $2.62M | - | $2.68M | $3.05M | $3.08M | - | $2.81M | $3.03M | $4.00M |
| Total Operating Expenses | $6.83M | $6.79M | - | $8.19M | $8.32M | $8.52M | - | $20.29M | $11.29M | $15.81M |
| D&A | - | $26.0K | - | - | - | $26.0K | - | - | - | $527.0K |
| Operating Income | ($2.75M) | ($2.76M) | - | ($4.00M) | ($5.13M) | ($6.71M) | - | ($18.71M) | ($11.40M) | ($15.57M) |
| Interest Expense | - | $185.0K | - | $341.0K | $372.0K | $402.0K | - | $1.00M | $823.0K | $872.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | ($4.67M) |
| Net Income | ($11.87M) | $1.28M | - | ($799.0K) | ($3.81M) | ($5.39M) | - | ($19.67M) | ($12.22M) | ($11.77M) |
| EPS - Basic | ($1.73) | $0.28 | - | ($0.27) | ($2.15) | ($5.91) | - | ($0.53) | ($8.00) | ($3.78) |
| EPS - Diluted | ($1.73) | $0.28 | - | ($0.27) | ($2.15) | ($5.91) | - | ($0.53) | ($8.00) | ($3.78) |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.85M | $2.62M | $2.56M | $2.87M | $2.79M | $4.43M | $5.25M | $6.14M | $13.03M | $3.74M |
| Accounts Receivable | $4.55M | $4.81M | $3.39M | $3.52M | $4.46M | $3.12M | $3.38M | $3.71M | $2.09M | $1.67M |
| Inventory | $5.79M | $3.75M | $2.74M | $2.41M | $2.54M | $2.21M | $1.33M | $1.80M | $2.34M | $2.69M |
| Accounts Payable | $16.54M | $12.62M | $9.57M | $6.88M | $6.16M | $10.36M | $7.73M | $4.91M | $12.04M | $9.54M |
| Current Assets | $14.44M | $11.99M | $9.53M | $10.06M | $11.65M | $10.91M | $11.36M | $15.49M | $18.47M | $14.35M |
| Total Assets | $14.96M | $12.61M | $10.26M | $10.89M | $12.57M | $13.70M | $14.24M | $18.46M | $32.83M | $29.30M |
| Current Liabilities | $26.23M | $21.44M | $20.78M | $17.54M | $15.31M | $18.51M | $13.39M | $11.65M | $28.78M | $25.85M |
| Long-term Debt | - | - | $1.51M | $1.59M | $1.56M | $1.51M | $1.43M | $1.32M | $12.63M | $12.25M |
| Total Liabilities | $36.88M | $22.93M | $26.57M | $23.30M | $24.69M | $23.13M | $19.79M | $12.20M | $29.41M | $26.56M |
| Stockholders' Equity | ($21.91M) | ($10.32M) | ($16.32M) | ($12.41M) | ($12.12M) | ($9.43M) | ($5.54M) | $6.26M | $3.42M | $2.74M |
| Retained Earnings | ($433.76M) | ($421.88M) | ($423.17M) | ($418.70M) | ($417.90M) | ($414.09M) | ($408.70M) | ($430.77M) | ($411.11M) | ($398.89M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($2.48M) | - | - | - | ($1.59M) | - | - | - | ($14.75M) |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | ($126.0K) |
| Financing Cash Flow | - | $2.54M | - | - | - | $778.0K | - | - | - | ($523.0K) |
| CapEx | - | - | - | - | - | - | - | - | - | $126.0K |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | ($14.88M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 73.2% | 70.6% | - | 62.8% | 58.1% | 47.5% | - | 52.5% | -4.9% | 13.3% |
| Operating margin | -49.2% | -48.2% | - | -60.0% | -93.1% | -175.9% | - | -623.2% | -536.1% | -884.3% |
| EBITDA margin | - | -47.8% | - | - | - | -175.2% | - | - | - | -854.4% |
| Net margin | -212.9% | 22.5% | - | -12.0% | -69.2% | -141.4% | - | -655.1% | -574.7% | -668.3% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -844.8% |
| FCF / Net income | - | - | - | - | - | - | - | - | - | 1.26 |
| R&D / Revenue | 9.6% | 8.7% | - | 10.6% | 12.8% | 20.0% | - | 26.2% | 40.3% | 71.4% |
| SG&A / Revenue | 45.1% | 45.8% | - | 40.2% | 55.4% | 80.9% | - | 93.8% | 142.3% | 227.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -79.3% | 10.2% | - | -7.3% | -30.3% | -39.4% | - | -106.5% | -37.2% | -40.2% |
| Return on equity | 54.2% | -12.4% | - | 6.4% | 31.4% | 57.1% | - | -314.2% | -357.4% | -429.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | -82.0% |
| Liquidity | ||||||||||
| Current ratio | 0.55 | 0.56 | 0.46 | 0.57 | 0.76 | 0.59 | 0.85 | 1.33 | 0.64 | 0.56 |
| Quick ratio | 0.33 | 0.38 | 0.33 | 0.44 | 0.60 | 0.47 | 0.75 | 1.17 | 0.56 | 0.45 |
| Cash ratio | 0.11 | 0.12 | 0.12 | 0.16 | 0.18 | 0.24 | 0.39 | 0.53 | 0.45 | 0.14 |
| Leverage | ||||||||||
| Debt / Equity | - | - | -0.09 | -0.13 | -0.13 | -0.16 | -0.26 | 0.21 | 3.69 | 4.47 |
| Debt / Assets | - | - | 0.15 | 0.15 | 0.12 | 0.11 | 0.10 | 0.07 | 0.38 | 0.42 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -14.9x | - | -11.7x | -13.8x | -16.7x | - | -18.6x | -13.8x | -17.9x |
| Equity multiplier | -0.68 | -1.22 | -0.63 | -0.88 | -1.04 | -1.45 | -2.57 | 2.95 | 9.60 | 10.68 |
| Liabilities / Assets | 2.46 | 1.82 | 2.59 | 2.14 | 1.96 | 1.69 | 1.39 | 0.66 | 0.90 | 0.91 |
| Efficiency | ||||||||||
| Asset turnover | 0.37 | 0.45 | - | 0.61 | 0.44 | 0.28 | - | 0.16 | 0.06 | 0.06 |
| Inventory turnover | 0.26 | 0.45 | - | 1.03 | 0.91 | 0.91 | - | 0.79 | 0.95 | 0.57 |
| Days sales outstanding | 298d | 307d | - | 193d | 296d | 299d | - | 451d | 358d | 345d |
| Days inventory outstanding | 1413d | 814d | - | 355d | 401d | 403d | - | 460d | 383d | 644d |
| Days payable outstanding | 4036d | 2742d | - | 1014d | 974d | 1888d | - | 1257d | 1969d | 2280d |
| Cash conversion cycle | -2325d | -1620d | - | -465d | -277d | -1186d | - | -345d | -1228d | -1291d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1.3% | 49.9% | - | 121.9% | 158.8% | 116.5% | - | 133.3% | 79.4% | 1418.1% |
| Revenue CAGR (3y) | 67.6% | 266.6% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 27.7% | 123.0% | - | 165.4% | - | 673.5% | - | - | - | - |
| Operating income growth (YoY) | 46.4% | 58.9% | - | 78.6% | 55.0% | 56.9% | - | -18.6% | 31.5% | 4.0% |
| Net income growth (YoY) | -211.7% | - | - | 95.9% | 68.8% | 54.2% | - | -17.3% | 30.7% | 31.3% |
| EPS growth (YoY) | 19.5% | - | - | 49.1% | 73.1% | -56.3% | - | -194.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | -0.9% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -80.8% | -9.4% | -194.3% | - | - | - | - | -41.4% | -86.1% | -92.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AGILE THERAPEUTICS INC against the 5 most active filers in the same SIC group.